News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

This is a difficult study to interpret.   There have been many trials of this vaccine. The early trials looked fantastic and this one looks pretty good.  However, the largest randomized phase 3  "ACT 4" trial showed no improvement in overall survival.  My thoughts are that the vaccine helps some people, with minimal side effects.  Not enough to be used by itself but might be part of the ultimate cocktail.  Treatments like this would be perfect candidates for the conditional approval pathway we are working on.


Posted on: 03/16/2020

Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740